ACTIVE

VESALE PHARMACEUTICA

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-362,9 k €-249,6 %over 1 year

Gross margin2,2 M €+109,0 %over 1 year

Equity3,1 M €-10,5 %over 1 year

Workforce2,8 ETP-53,3 %over 1 year

Identity

Source · BCE/KBO

VESALE PHARMACEUTICA is a Public limited company incorporated in 1994. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Gembloux. It employs on average 2,8 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0452.282.591
Incorporation: 16/03/1994
Legal form: Public limited company
Registered office: Rue Jean Sonet,Isnes 29
5032 Gembloux · WallonieSee on map
Contributed capital: 2 300 000,00 €
Latest accounts: 31/12/2025
Average workforce: 2,8 ETP

Activities (NACE)

46460Wholesale of pharmaceutical goods· main 46460Wholesale of pharmaceutical goods 51460Air transport 46450Wholesale of perfume and cosmetics 46450Wholesale of perfume and cosmetics 51450Air transport

Joint committees (1)

Signals

Solid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 23 filings

Trend over 18 financial years

	2025		2024		2023		2022		2021
Income statement
Gross margin	2,2 M €	+109%	1,1 M €	-1.6%	1,1 M €	-0.1%	1,1 M €	+23.5%	865,5 k €
EBITDA	1,4 M €	+172%	520,7 k €	+7.8%	483,2 k €	-6.5%	516,9 k €	+269%	139,9 k €
Operating result	225,4 k €	-13.5%	260,5 k €	-0.2%	261,1 k €	-29.4%	370 k €	+966%	-42,7 k €
Net result	-362,9 k €	-250%	242,6 k €	+17.7%	206,1 k €	-39.5%	340,5 k €	+651%	-61,8 k €
Balance sheet
Equity	3,1 M €	-10.5%	3,5 M €	+7.5%	3,2 M €	+6.8%	3 M €	+12.7%	2,7 M €
Total assets	4 M €	-11.0%	4,5 M €	-8.5%	4,9 M €	-9.5%	5,5 M €	+27.9%	4,3 M €
Cash	1,5 M €	+1147%	120,9 k €	+22.8%	98,4 k €	-10.1%	109,5 k €	+59.7%	68,6 k €
Debts	919,8 k €	-0.3%	922,4 k €	-41.9%	1,6 M €	-32.8%	2,4 M €	+48.5%	1,6 M €
Other
Workforce	2,8 ETP	-53.3%	6,0 ETP	-14.3%	7,0 ETP	+14.8%	6,1 ETP	-28.2%	8,5 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 5 M€ and 10 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

6 active · 7 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Aquitania0666.678.822Represented by Anja Imschoot	Director14/05/2025 → 30/06/2031
Jehan Lienart van Lidth de Jeude	Director14/05/2025 → 31/12/2025Managing director13/06/2008 → 2009 accountsended
MD CONSULT0471.608.456Represented by Mario Debel	Director14/05/2025 → 30/06/2031
Nathalie Géruzet	Director13/06/2008 → 14/05/2025
RODE VENTURES0836.174.741Represented by Pierre Iweins d'Eechoutte	Director08/07/2019 → 14/05/2025
Vesale Pharma International SARepresented by Jehan Lienart van Lidth de Jeude	Managing director08/07/2019 → 14/05/2025

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Johan Quintens	Director13/06/2008 → 2009 accounts
BALARDES0474.082.649	Director29/04/2005 → 2008 accounts
JEHAN Mr LIENART VAN LINDTH DE JEUDE	Managing director29/04/2005 → 2008 accounts
Philippe Mr VANDIEST	Director29/04/2005 → 2008 accounts

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	29/07/2026	14/08/2025	07/08/2025	29/08/2023	29/08/2022	31/08/2021
General meeting	30/06/2026	30/06/2025	28/06/2024	30/06/2023	30/06/2022	30/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 23 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	30/06/2026	29/07/2026	French	PDF
Abridged model	31/12/2024	30/06/2025	14/08/2025	French	PDF
Abridged modelCorrection	31/12/2023	28/06/2024	07/08/2025	French	PDF
Abridged model	31/12/2023	28/06/2024	22/08/2024	French	PDF
Abridged model	31/12/2022	30/06/2023	29/08/2023	French	PDF
Abridged model	31/12/2021	30/06/2022	29/08/2022	French	PDF
Abridged model	31/12/2020	30/06/2021	31/08/2021	French	PDF
Abridged model	31/12/2019	14/05/2020	15/07/2020	French	PDF
Abridged model	31/12/2018	29/06/2019	30/09/2019	French	PDF
Abridged model	31/12/2017	30/06/2018	31/08/2018	French	PDF
Abridged model	31/12/2016	30/06/2017	28/08/2017	French	PDF
Abridged model	31/12/2015	30/06/2016	24/08/2016	French	PDF
Abridged model	31/12/2014	30/06/2015	02/07/2015	French	PDF
Abridged model	31/12/2013	30/06/2014	13/08/2014	French	PDF
Abridged model	31/12/2012	29/06/2013	02/08/2013	French	PDF
Abridged model	31/12/2011	30/06/2012	04/07/2012	French	PDF
Abridged modelCorrection	31/12/2010	25/09/2011	27/09/2011	French	PDF
Abridged model	31/12/2010	30/06/2011	31/08/2011	French	PDF
Abridged modelCorrection	31/12/2009	30/06/2010	08/04/2011	French	PDF
Abridged model	31/12/2009	30/06/2010	31/08/2010	French	PDF
Abridged model	31/03/2008	01/09/2008	20/11/2008	French	PDF
Abridged model	31/03/2007	01/09/2007	30/11/2007	French	PDF
Abridged model	31/03/2006	06/09/2006	14/05/2007	French	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 5 M€ and 10 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

6 active · 7 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Aquitania0666.678.822Represented by Anja Imschoot	Director14/05/2025 → 30/06/2031
Jehan Lienart van Lidth de Jeude	Director14/05/2025 → 31/12/2025Managing director13/06/2008 → 2009 accountsended
MD CONSULT0471.608.456Represented by Mario Debel	Director14/05/2025 → 30/06/2031
Nathalie Géruzet	Director13/06/2008 → 14/05/2025
RODE VENTURES0836.174.741Represented by Pierre Iweins d'Eechoutte	Director08/07/2019 → 14/05/2025
Vesale Pharma International SARepresented by Jehan Lienart van Lidth de Jeude	Managing director08/07/2019 → 14/05/2025

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Johan Quintens	Director13/06/2008 → 2009 accounts
BALARDES0474.082.649	Director29/04/2005 → 2008 accounts
JEHAN Mr LIENART VAN LINDTH DE JEUDE	Managing director29/04/2005 → 2008 accounts
Philippe Mr VANDIEST	Director29/04/2005 → 2008 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates24/02/2026
DEMISSIONS, NOMINATIONS
PDF
Registered office27/01/2026
SIEGE SOCIAL
PDF
Mandates18/06/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates06/07/2020
DEMISSIONS, NOMINATIONS
PDF
Mandates10/06/2020
CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
PDF
Mandates19/07/2019
DEMISSIONS, NOMINATIONS
PDF
Capital / shares24/04/2019
CAPITAL, ACTIONS
PDF
Capital / shares13/01/2016
CAPITAL, ACTIONS
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings18 filings

Mandates

MD CONSULT

Aquitania

Jehan Lienart van Lidth de Jeude

Nathalie Géruzet

RODE VENTURES

Vesale Pharma International SA

Johan Quintens

BALARDES

JEHAN Mr LIENART VAN LINDTH DE JEUDE

Philippe Mr VANDIEST

Pharmadis

Pharmadis SA

Show the other mandate

19941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031

VESALE PHARMACEUTICA

Rue Jean Sonet,Isnes 29, 5032 Mazyrue Louis Allaert 9, 5310 Eghezée

Director

DirectorManaging director

Director

Managing director

Director

Managing director

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Rue Jean Sonet,Isnes 29, 5032 MazyCurrent	accounts 2024 → 2025	Accounts 2025 · 2026-00352173
rue Louis Allaert 9, 5310 Eghezée	accounts 2021 → 2023	Accounts 2023 · 2025-00366958

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
VESALE PHARMACEUTICACurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00352173

Events

2025
Annual accounts 2025-362,9 k €↓
2024
Annual accounts 2024242,6 k €↑
2023
Annual accounts 2023206,1 k €↓
2022
Annual accounts 2022340,5 k €↑
2021
Annual accounts 2021-61,8 k €↓
2020
Annual accounts 2020434,7 k €↑
2019
Annual accounts 2019-2,4 M €↑
2018
Annual accounts 2018-2,5 M €↓
2017
Annual accounts 2017-242,7 k €↓
2016
Annual accounts 201614,3 k €↓
2015
Annual accounts 201533,3 k €↑
2014
Annual accounts 201427,3 k €↑
2013
Annual accounts 20135 k €↑
2012
Annual accounts 2012-59 k €↓
2011
Annual accounts 20119,5 k €↑
2010
Annual accounts 2010-24,7 k €↓
2009
Annual accounts 200975,1 k €↑
2008
Annual accounts 200816 k €
16/03/1994
IncorporationPublic limited company

VESALE PHARMACEUTICA

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events